Oegstgeest, The Netherlands, 24 October 2023 – ISA is pleased to announce that it will be presenting during the 4th Annual H.C. Wainwright Virtual HBV Conference – October 25th. The presentation by Gerben Moolhuizen, CEO of ISA Pharmaceuticals, will highlight key characteristics and progress in the development of ISA104, a therapeutic vaccine aimed to aid in achieving functional cure of patients suffering from chronic hepatitis B infection.
4th Annual Virtual H.C. Wainwright HBV Conference
Date: 25 October 2023
Presentation title: Targeted Immune System Activation using SLPs in chronic HBV
Time: 5:00 – 5:30pm CET
ISA104 immunotherapy has been designed to create a strong andRead more »